The short version of cyclic peptide fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-03-19. Anything still debated is marked as such rather than presented as settled.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Bremelanotide functions as an agonist at several melanocortin receptor subtypes, with the strongest functional activity reported at the MC4 subtype. MC4 receptors sit in hypothalamic circuits that influence appetite, energy balance, and components of sexual behaviour. Rodents lacking functional MC4 receptors show altered mating behaviour, which supports a role for this pathway in desire. The precise sequence of events connecting receptor activation to reported human effects remains only partly characterised. Because the same receptor family governs pigmentation and inflammatory signalling, selectivity is a recurring theme in pharmacological discussion.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic melanocortin analogue |
| Molecular formula | C50H68N14O10 | Corresponds to a mass near 1025 daltons |
| Appearance | White to off-white powder | Lyophilised solid before reconstitution |
| Solubility | Soluble in water and polar solvents | Poor solubility in nonpolar media |
| Common synonyms | Bremelanotide, PT-141 | Code name and international name used interchangeably |
Outside the approved product, bremelanotide circulates as a research chemical sold by peptide vendors, often labelled PT-141. Such material is not manufactured under pharmaceutical quality standards, and independent testing has repeatedly found content that differs from the label. Analytical certificates supplied with a purchase are not strong evidence of purity because they are usually generated by the seller. Online discussion tends to blur the distinction between the approved drug and unregulated powder, which complicates interpretation of reported experiences.
PT-141 is the original development code for bremelanotide, a synthetic peptide first studied as a potential tanning and sexual-response agent in the 1990s. Researchers at a small American biotechnology firm designed it as a shortened analogue of melanotan II, which itself came from work on alpha-melanocyte-stimulating hormone. Early screening focused on pigmentation, but behavioural observations in animal models redirected attention toward sexual motivation. That shift made PT-141 one of the first melanocortin compounds investigated specifically for effects on desire rather than on skin colour.
Clinical development proceeded through two routes of administration. An intranasal formulation advanced first, but variable absorption and tolerability problems led to a switch to subcutaneous injection. The United States Food and Drug Administration approved the subcutaneous product in 2019 for hypoactive sexual desire disorder in premenopausal women. Marketing rights subsequently changed hands, and commercial availability has fluctuated since approval. Use in men, in postmenopausal women, and in combination with other agents remains outside the approved label.
Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Certificate of analysis documents usually report purity percentage, molecular weight, and appearance. Researchers verify identity by comparing observed and theoretical mass values. Chain-of-custody records and batch numbers help trace material from source to experiment. Independent verification of supplier claims is considered good practice when material identity is critical to a study. Records should include the storage history of each aliquot, and unexpected deviations in appearance or solubility warrant re-testing before use.
Lyophilized peptide material is generally stored at -20 °C or below to limit degradation, while reconstituted solutions are less stable and are typically kept refrigerated and protected from light. Repeated freeze-thaw cycles can accelerate aggregation and should be minimized. Stability for any specific lot depends on purity, moisture content, and packaging. Handling in a temperature-controlled environment reduces variability across replicates, and exposure to ambient humidity during weighing can introduce error. Aliquotting reduces the number of times a stock container is opened.
==== South Africa ==== Codeine is available over the counter in South Africa. Certain pharmacies require people to write down their name and address to ensure they are not buying too much over a short period although many do not require this at all. According to Lochan Naidoo, the former president of the National Narcotics Control Board, making the drugs more difficult to obtain could lead to even worse problems where people in withdrawal would turn to illicit drugs to get their fix.
==== European Union ==== Danish pharmaceutical company Lundbeck has licensed nalmefene from Biotie Therapies and performed clinical trials with nalmefene for treatment of alcohol dependence. In 2011, they submitted an application for their medication named Selincro to the European Medicines Agency. The medication was authorized for use in the EU in March 2013. and in October 2013, Scotland became the first country in the EU to prescribe the drug for alcohol dependence. England followed Scotland by offering the medication as a treatment for problem drinking in October 2014. In November 2014, nalmefene was approved as a possible treatment supplied by Britain's National Health Service (NHS) for reducing alcohol consumption in people with alcohol dependence.
Although MASLD can cause cirrhosis, liver failure, and liver cancer, most deaths among people with MASLD are attributable to cardiovascular disease. According to a meta-analysis of 34,000 people with MASLD over seven years, these individuals have a 65% increased risk of developing fatal or nonfatal cardiovascular events when compared to those without MASLD. MASLD and MASH increase the risk of liver cancer. Cirrhosis and liver cancer induced by MASLD or MASH were the second cause of liver transplantation in the US in 2017, with MASLD or MASH expected to overtake alcohol related liver disease as the most common indication for a liver transplantation in the future. People with MASH cirrhosis have an increased risk of liver cancer. The rate of liver cancer associated with MASH increased fourfold between 2002 and 2012 in the US, which is more than any other cause of liver cancer. MASLD constitutes the third most common risk factor for liver cancer. Cirrhosis is found in only about 50% of people with MASLD and with liver cancer, so liver cancer may occur without cirrhosis being present. MASLD and MASH also increase the risk of non-liver cancers, especially cancers of the gastrointestinal tract such as colon cancer. MASLD is a precursor of metabolic syndrome, although a bidirectional influence is possible. The presence and stage of fibrosis are the strongest prognostic factors for liver-related events and mortality, in particular for MASLD.
In 1928, Grace and Pan American Airways jointly formed Pan American-Grace Airways known as Panagra, establishing the first air link between North and South America, which began operation in 1929. In 1967, Panagra merged with Braniff International Airways.
7 June Rishi Sunak is criticised for leaving the D-day commemorations early to return to the UK to work on the election campaign. He says: "On reflection, it was a mistake not to stay in France longer – and I apologise." Data produced by Zoopla indicates that rents for new properties rose by 6.6% in the year to April 2024, but that this was the slowest rise in two and a half years. 9 June – Restrictions on carrying more than 100ml of liquid in hand luggage are temporarily reintroduced at some regional airports in order to "enable further improvements to be made" to new checkpoint systems. Those affected are Newcastle, Leeds Bradford, London City, Aberdeen, Southend and Teesside. 10 June – Twenty buildings across the UK are vandalised as part of a co-ordinated attack by Palestine Action, a pro-Palestine group. 11 June A High Court judge rules that convicted sex offender Gary Glitter must pay more than £500,000 to a victim he abused when she was 12 years old. A 28-year-old man is arrested on suspicion of public order offences after objects are thrown at Nigel Farage during a campaign tour in Barnsley. Rishi Sunak unveils the Conservative Party's general election manifesto, which includes a further cut in National Insurance, a halving of immigration, and several new housing policies. Former UN secretary general Ban Ki-moon is awarded the inaugural King Charles III Harmony Award during a ceremony held at St James's Palace. Two animal rights protestors vandalise a portrait of Charles III at London's Philip Mould Gallery by covering it with posters.
Sources: en.wikipedia.org
Nandrolone is the parent compound of a large group of anabolic steroids. Notable examples include the non-17α-alkylated trenbolone and the 17α-alkylated ethylestrenol (ethylnandrol) and metribolone (R-1881), as well as the 17α-alkylated designer steroids norboletone and tetrahydrogestrinone (THG). The following is list of derivatives of nandrolone that have been developed as anabolic steroids:
=== Bioelectricity === The potential use of developmental bioelectricity in regenerative medicine is under active investigation, with particular interest in future organ and limb regeneration guided by bioelectric stimulation. Developmental bioelectricity refers to endogenous ion flows and voltage gradients across cell membranes (Vmem) in excitable (able to create an action potential) and non-excitable tissues that provide instructive cues for growth. These bioelectric states, set by ion channels and pumps, are propagated through gap-junction coupling and together with chemical gradients and physical forces they form long-range patterning circuits. Through voltage-sensitive signalling pathways, changes in Vmem modulate gene expression and cell behaviours (proliferation, migration, differentiation), thereby shaping tissue growth and polarity. Experiments in vertebrate and invertebrate models indicate that bioelectric cues can steer regeneration. In Xenopus tadpoles, activating a proton pump (V-ATPase) that moves hydrogen ions out of cells is necessary for tail regrowth and can restore regeneration during a normally refractory stage; in adult Zebrafish, inhibiting the same pump impairs fin regrowth. In Planarians, brief electrical perturbations can cause tail pieces to form heads (including two-headed animals) or to regenerate heads resembling other species. In adult frogs, a 24-hour treatment with a drug-delivering ‘BioDome’ device initiated long-term hindlimb regrowth with multi-tissue repair and functional recovery.
In February 2010, the German Research Foundation published new guidelines to reduce the number of publications that could be submitted when applying for funding: "The focus has not been on what research someone has done but rather how many papers have been published and where." They noted that for decisions concerning "performance-based funding allocations, postdoctoral qualifications, appointments, or reviewing funding proposals, [where] increasing importance has been given to numerical indicators such as the h-index and the impact factor". The UK's Research Assessment Exercise for 2014 also banned the journal impact factor although evidence suggested that this ban was often ignored. In response to growing concerns over the inappropriate use of journal impact factors in evaluating scientific outputs and scientists themselves, the American Society for Cell Biology together with a group of editors and publishers of scholarly journals created the San Francisco Declaration on Research Assessment (DORA). Released in May 2013, DORA has garnered support from thousands of individuals and hundreds of institutions, including in March 2015 the League of European Research Universities (a consortium of 21 of the most renowned research universities in Europe), who have endorsed the document on the DORA website. Publishers, even those with high impact factors, also recognised the flaws.
The integration of different regulatory signals by gonadotropes results in the coordinated control of production and secretion of gonadotropins to respond and control sexual maturation and reproductive functions.
The island is known for using geothermal energy to provide electricity for its inhabitants. In San Carlos, Negros Occidental where energy company San Carlos Solar Energy (SaCaSol) is located, solar energy is being used to power the city and surrounding municipalities. Inland towns and cities of Negros uses hydroelectric power acquired from springs, rivers and waterfalls. Due to the island region's sugarcane-based agriculture, Negros may become the nation's major biofuel producer, with sugarcane being used for ethanol production.
Sources: en.wikipedia.org
The WHO urban air quality database estimated Delhi's mean annual PM 10 levels in 2010 as 286 μg /m3 and London as 23 μg /m3. In 2014, the database estimated Delhi's annual mean PM 2.5 particulate matter levels in 2013 as 156 μg /m3 whereas, London have only 8 μg /m3 in 2010 but the nitrogen dioxide in London breach the European Union's standard. In 2013, the annual mean nitrogen dioxide level in London was estimated as 58 μg /m3 but the save and "threshold limit value" is 40 μg /m3. In March 2015, Brussels took the United Kingdom into court for breaching emissions limits of nitrogen dioxide at its coal-fired Aberthaw power stations in Wales. The plant operated under a permit allowing emissions of 1200 mg/Nm3, which is more than twice the 5 mg/Nm3 limit specified in the EU's large combustion plant directive.
Gone with the Wind—first released in 1939—is generally considered to be the most successful film, with Guinness World Records in 2014 estimating its adjusted global gross at $3.4 billion. Estimates for Gone with the Wind's adjusted gross have varied substantially: its owner, Turner Entertainment, estimated its adjusted earnings at $3.3 billion in 2007, a few years earlier than the Guinness estimate; other estimates fall either side of this amount, with one putting its gross just under $3 billion in 2010, while another provided an alternative figure of $3.8 billion in 2006. Which film is Gone with the Wind's nearest rival depends on the set of figures used: Guinness had Avatar in second place with $3 billion, while other estimates saw Titanic in the runner-up spot with first-run worldwide earnings of almost $2.9 billion at 2010 prices.
== Applications == BMP has been shown to remain stable, without breaking down, in high-heat pasteurization and sterilization conditions, making it possible for potential use for culinary purposes. Those advocating for the presence of BMP's flavor-enhancing umami taste report that its taste is similar to that of monosodium glutamate. Consequently, BMP possesses potential for large-scale commercialization in the food industry. However, the primary obstacle is the cost of mass production associated with the peptide. Currently, the main modes of production for specific flavor peptides such as BMP are chemical and enzymatic synthesis, both of which involve high production costs.
=== Central & East Indo-Pacific === 2024 Vietnamese export of pangasius maw has increased to about US$58,000,000, with 38% going to China and the rest to Thailand, Malaysia, Singapore and the USA. The Vietnam News Agency claims that the falling totoaba population has incentivized Chinese import of alternative maw. The island and seas of New Guinea see significant fish maw production. Since 2012, in and around the Kikori River delta of Papua New Guinea, the scaly croaker Nibea squamosa has been targeted in gillnetting for its extremely high-priced maw, selling for as much as US$15,615 per kilogram.
Sources: en.wikipedia.org
PT-141 is a laboratory code for bremelanotide, a synthetic peptide that activates melanocortin receptors. It has been developed both as an injectable pharmaceutical product and as a research chemical. The two contexts differ sharply in how identity, purity, and dosing are controlled.
It is neither a steroid nor a naturally occurring human hormone. Bremelanotide is a manufactured peptide that mimics part of the melanocortin signalling system by binding receptor proteins. Its effects come from receptor activation, not from replacing a circulating hormone.
The internal lactam bridge locks the peptide into a defined shape, which raises receptor affinity and slows enzymatic breakdown. Linear versions of the same sequence are less stable and bind more weakly. Ring geometry is therefore central to how the molecule behaves in the body.
The approved formulation is given by subcutaneous injection and is used on an as-needed basis rather than on a fixed daily schedule. An intranasal version was studied earlier but did not reach the same stage of development. Route of delivery strongly affects how quickly the peptide appears in circulation.